Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Gurwitz

Showing results (31-40 of 142) with videos related to

Pageof 15
Sort By:
Journal of the National Cancer Institute|September 11, 2008
Re: Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysisDavid Gurwitz, William Newman
Drug Development Research|February 1, 2022
Estradiol reduces ACE2 and TMPRSS2 mRNA levels in A549 human lung epithelial cellsGabriele Baristaite, David Gurwitz
Drug Development Research|October 22, 2021
d-Galactose treatment increases ACE2, TMPRSS2, and FURIN and reduces SERPINA1 mRNA expression in A549 human lung epithelial cellsGabriele Baristaite, David Gurwitz
Pharmacogenomics|March 31, 2010
Pharmacogenomics: the importance of accurate phenotypesDavid Gurwitz, Munir Pirmohamed
Drug Discovery Today|March 28, 2002
The NR2B subunit of glutamate receptors as a potential target for relieving chronic pain: prospects and concernsDavid Gurwitz, Abraham Weizman
Drug Development Research|October 10, 2023
Artificial intelligence utility for drug development: ChatGPT and beyondDavid Gurwitz, Noam Shomron
Personalized Medicine|May 24, 2018
Workshop Introduction: Personalized medicine: desirable, affordable, attainable?David Gurwitz, Gregory Livshits
Lancet (London, England)|April 17, 2002
Seasonality of birth in patients with type 1 diabetesDavid Gurwitz, Abraham Weizman
Dialogues in Clinical Neuroscience|April 3, 2019
Peripheral transcriptomic biomarkers for early detection of sporadic Alzheimer disease?Adva Hadar, David Gurwitz
Pharmacogenomics|February 27, 2013
Genome-wide studies in pharmacogenomics: harnessing the power of extreme phenotypesDavid Gurwitz, Howard L McLeod
Pageof 15

Showing results (31-40 of 142) with videos related to

Sort By:
Pageof 15
Journal of the National Cancer Institute|September 11, 2008
Re: Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysisDavid Gurwitz, William Newman
Drug Development Research|February 1, 2022
Estradiol reduces ACE2 and TMPRSS2 mRNA levels in A549 human lung epithelial cellsGabriele Baristaite, David Gurwitz
Drug Development Research|October 22, 2021
d-Galactose treatment increases ACE2, TMPRSS2, and FURIN and reduces SERPINA1 mRNA expression in A549 human lung epithelial cellsGabriele Baristaite, David Gurwitz
Pharmacogenomics|March 31, 2010
Pharmacogenomics: the importance of accurate phenotypesDavid Gurwitz, Munir Pirmohamed
Drug Discovery Today|March 28, 2002
The NR2B subunit of glutamate receptors as a potential target for relieving chronic pain: prospects and concernsDavid Gurwitz, Abraham Weizman
Drug Development Research|October 10, 2023
Artificial intelligence utility for drug development: ChatGPT and beyondDavid Gurwitz, Noam Shomron
Personalized Medicine|May 24, 2018
Workshop Introduction: Personalized medicine: desirable, affordable, attainable?David Gurwitz, Gregory Livshits
Lancet (London, England)|April 17, 2002
Seasonality of birth in patients with type 1 diabetesDavid Gurwitz, Abraham Weizman
Dialogues in Clinical Neuroscience|April 3, 2019
Peripheral transcriptomic biomarkers for early detection of sporadic Alzheimer disease?Adva Hadar, David Gurwitz
Pharmacogenomics|February 27, 2013
Genome-wide studies in pharmacogenomics: harnessing the power of extreme phenotypesDavid Gurwitz, Howard L McLeod
Pageof 15